Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-10-14
2010-02-23
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S403000
Reexamination Certificate
active
07666889
ABSTRACT:
The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.
REFERENCES:
patent: 6476060 (2002-11-01), Lange et al.
patent: 6974810 (2005-12-01), Lange et al.
patent: 7528162 (2009-05-01), Kruse et al.
patent: 1429761 (2006-11-01), None
Lange, J.H.M. et al.; Synthesis, Biological Properties and Molecular Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB1 Cannabinoid Receptor Antagonists; J. Med. Chem. 2004, 47, 627-643.
Remington et al.; The Science and Practice of Pharmacy, 2000, Lippincott Williams and Wilkins, 20th Edition, pp. 218-220.
PCT/US2007/068342 International Search Report and Written Opinion of the corresponding parent application, May 16, 2008.
Wierzbicki, A.S., Rimonabant: endocannabinoid inhibition for the metabolic syndrome, Drug Focus 2006, 60(12), 1697-1706.
Pi-Sunyer, F.X., Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients, JAMA 2006, 297(7), 761-775.
Solvay's SLV319 Obesity Candidate Treatment Advances in Phase II Clinical Trials, Solvay Press Release, Dec. 8, 2006.
Stradivarius (Strategy To Reduce Athersclerosis Development InVolving Administration of Rimonabant—the Intravascular Ultrasound Study), ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/study/NCT00124332, [retrieved on Aug. 6, 2009] last updated Apr. 17, 2009.
Chorvat Robert J.
McElroy John F.
Bianchi Kristin
Jenrin Discovery, Inc.
Saeed Kamal A
Vance Intellectual Property, PC
LandOfFree
Cannabinoid receptor antagonists/inverse agonists useful for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cannabinoid receptor antagonists/inverse agonists useful for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cannabinoid receptor antagonists/inverse agonists useful for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4234994